Gilead Sciences Inc. (NASDAQ:GILD)’s share price was up 3% on Tuesday . The company traded as high as $81.67 and last traded at $81.35, with a volume of 8,312,668 shares. The stock had previously closed at $78.99.

A number of equities analysts have recently weighed in on GILD shares. Piper Jaffray Cos. reiterated a “buy” rating and set a $108.00 target price on shares of Gilead Sciences in a research note on Monday, August 15th. Jefferies Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $76.89 to $91.00 in a research note on Tuesday, September 6th. Morgan Stanley reiterated a “hold” rating and set a $103.00 target price on shares of Gilead Sciences in a research note on Wednesday, June 15th. Berenberg Bank assumed coverage on Gilead Sciences in a research note on Monday, September 12th. They set a “buy” rating and a $112.00 target price on the stock. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Sunday, July 10th. Nine research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $105.41.

The stock has a 50-day moving average of $79.27 and a 200 day moving average of $86.05. The company has a market capitalization of $107.92 billion, a price-to-earnings ratio of 7.18 and a beta of 1.06.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/gilead-sciences-inc-gild-trading-up-3.html

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same quarter in the previous year, the firm posted $3.15 EPS. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences Inc. will post $11.77 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.30%. Gilead Sciences’s payout ratio is 16.56%.

In other news, insider John F. Milligan sold 70,000 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the transaction, the insider now directly owns 1,128,963 shares in the company, valued at approximately $87,765,583.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $83.12, for a total transaction of $166,240.00. Following the transaction, the executive vice president now owns 63,122 shares of the company’s stock, valued at $5,246,700.64. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CENTRAL TRUST Co bought a new position in shares of Gilead Sciences during the first quarter valued at about $10,862,000. Lau Associates LLC raised its position in shares of Gilead Sciences by 0.7% in the first quarter. Lau Associates LLC now owns 29,400 shares of the biopharmaceutical company’s stock valued at $2,701,000 after buying an additional 200 shares during the period. Denali Advisors LLC bought a new position in shares of Gilead Sciences during the first quarter valued at about $1,920,000. DnB Asset Management AS raised its position in shares of Gilead Sciences by 99.4% in the first quarter. DnB Asset Management AS now owns 231,282 shares of the biopharmaceutical company’s stock valued at $21,246,000 after buying an additional 115,300 shares during the period. Finally, Nexus Investment Management Inc. raised its position in shares of Gilead Sciences by 4.4% in the first quarter. Nexus Investment Management Inc. now owns 198,850 shares of the biopharmaceutical company’s stock valued at $18,266,000 after buying an additional 8,300 shares during the period. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.